Breakthrough drug combination targets KRAS mutation in lung cancer

A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib-an FDA-approved drug in the market-and an experimental drug called FGTI-2734, which could make precision medicine more effective for patients with a highly resistant form of lung cancer.